Abstract 443P
Background
Many patients with advanced cancer have difficulty eating and need nutritional support. This preliminary study examined the effects of individual nutritional counselling sessions on quality of life (QOL), nutritional status and eating-related distress (ERD) among patients with advanced cancer undergoing chemotherapy.
Methods
A survey was conducted in the outpatient chemotherapy center at a university hospital in Tokyo, Japan. Patients were offered individual nutritional counselling by a dietitian specializing in cancer. For the participants who completed at least two counselling sessions, we evaluated changes in their QOL (EORTC-QLQ C30), symptoms and nutritional status (PG-SGA SF) and ERD. Data were analyzed using the Wilcoxon signed rank test to compare mean differences. The ethics committee approved the study (Ethical Review No. M2015-578).
Results
Of 42 patients who applied for nutritional counselling, 8 underwent two sessions. The mean age was 70.6 ± 5.9 years and females accounted for 25.0%. Primary diseases were gastrointestinal cancer (n = 6) and lung cancer (n = 2). “Although family members and friends recommend foods to me, I am just confused” on the ERD and “fatigue” on the EORTC-QLQ C30 significantly improved (p < 0.05, respectively). There were no significant differences in the other items of the EORTC-QLQ C30 or symptoms and nutritional status on the PG-SGA SF. In total, 34 patients did not receive nutritional counselling twice because of death, changing hospitals, disease progression, or lack of coordination among researchers.
Conclusions
Our study suggests that individual nutritional counselling is slightly beneficial for patients with advanced cancer receiving chemotherapy. Further research is needed to demonstrate the effectiveness of this intervention in the future.
Clinical trial identification
UMIN registration No. UMIN000021540; was carried out prior to the start of the study.
Editorial acknowledgement
Legal entity responsible for the study
Tokyo Medical and Dental University.
Funding
Sasakawa Memorial Health Foundation.
Disclosure
S. Koshimoto: Research grant / Funding (institution): Sasakawa Memorial Health Foundation. All other authors have declared no conflicts of interest.
Resources from the same session
51P - Enhancing the anti-breast tumour activity of STING through a novel sting transcriptional regulator
Presenter: Hanchu Xiong
Session: Poster display session
Resources:
Abstract
52P - Reverse Warburg effect-related mitochondrial activity and 18F-FDG uptake in invasive ductal carcinoma
Presenter: Byung Wook Choi
Session: Poster display session
Resources:
Abstract
53P - Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Final analysis report
Presenter: Abdullah Altwairgi
Session: Poster display session
Resources:
Abstract
54P - Association between Parkinson’s disease and brain tumours: A nationwide population-based cohort study
Presenter: Joo-hyun Park
Session: Poster display session
Resources:
Abstract
55P - Toxicity profiles of treatment with modern fractionated radiotherapy, contemporary stereotactic radiosurgery, or transsphenoidal surgery in non-functioning pituitary macroadenoma
Presenter: Kevin Sheng-Po Yuan
Session: Poster display session
Resources:
Abstract
56P - Hippocampal avoidance in WBRT for metastases: Comparative neurocognitive and dosimetric assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
57P - Multidisciplinary brain metastasis clinic: Is it effective and worthwhile?
Presenter: Annu Rajpurohit
Session: Poster display session
Resources:
Abstract
58P - Functional status as a determinant prognostic factor for overall survival in adult patients with medulloblastoma treated with chemotherapy and radiotherapy
Presenter: Juan Ayala Alvarez
Session: Poster display session
Resources:
Abstract
59P - Pattern of care in high-grade gliomas after recurrence
Presenter: Nandini Menon
Session: Poster display session
Resources:
Abstract
60P - Five fractions plus “SRS” boost combined with temozolamide for newly diagnosed and recurrent glioblastoma multiforme (GBM)
Presenter: Azhar Rashid
Session: Poster display session
Resources:
Abstract